Abstract. Seven monoclonal antibodies (Moabs), recognizing melanoma-associated antigens in human tissues, were evaluated for their ability to immunohistochemically stain formalin-fixed, paraffin-embedded canine melanomas. Only 2 Moabs, designated human melanosome-specific antigen (HMSA)-1 and HMSA-5, stained routinely processed canine melanomas, staining 2 1 /3 5 (60%) and 24/35 (69%), respectively. Twenty-nine of 35 (83%) melanomas tested were stained if results of the 2 Moabs were combined. Monoclonal antibody HMSA-1 also stained neoplastic cells of 10/35 (29%) tumors of nonmelanocytic origin and some neurons and salivary gland epithelial cells in normal canine tissues. However, Moab HMSA-1 staining in the nonmelanocytic tumors, consisting of small, discrete periodic acid-Schiff-positive cytoplasmic droplets, was readily distinguishable from the diffusely granular, cytoplasmic staining of melanocytic tumors. In addition to melanomas, Moab HMSA-5 stained melanocytes and some melanin-containing tumor cells of a pigmented basal cell tumor and melanocytes in normal canine skin. Monoclonal antibodies HMSA-1 and HMSA-5 immunohistochemically identified the majority of canine melanomas, had limited and distinguishable staining in normal tissues and nonmelanocytic tumors, and therefore may be a useful adjunct for the diagnosis of canine melanoma in formalin-fixed, paraffinembedded tissues.
Immunohistochemical stains are routinely used in human surgical pathology to facilitate tumor diagnosis in cases of poorly differentiated neoplasms. Recently, there have been several reports of immunohistochemical techniques for improved tumor diagnosis in aniMelanomas represent between 4% and 7% of all tumors and from 9% to 20% of skin tumors in the and include both benign and malignant variants. Malignant melanoma is the most common malignancy of the oropharynx in this specie^.^,^ Histologically, some melanomas are difficult to distinguish from poorly differentiated carcinomas and sarcomas. Traditional methods of distinguishing melanomas from other neoplasms include argyrophil stains such as the Masson Fontana silver stain or demonstration of dihydroxyphenylalanine oxidase (DOPA) activity by histochemical techniques. The utility of these techniques is limited because the DOPA reaction is best performed on fresh frozen tissue sections and the Masson Fontana stain reacts with substances other than melanin, such as lipofuscin and argentaffin granules of neurosecretory cells. 22 The advent of monoclonal antibody technology15 has allowed development of highly specific reagents for more precise identification of cell and tissue antigens. ma1s.2,3,7.8. 18.20,21.26 Monoclonal antibodies (Moabs) specific for melanoma-associated antigens in humans,1.4,5.10.13,17,23-25 and recently in dogs,18 have been developed and are reported to identify epitopes that withstand fixation in formalin and embedment in paraffin.
The purpose of this investigation was to test Moabs raised against human melanoma-associated antigens on formalin-fixed, paraffin-embedded canine neoplastic and nonneoplastic tissues to assess their potential utility as ancillary diagnostic tools for the diagnosis of melanocytic tumors in dogs.
Materials and Methods
Monoclonal antibodies (Moabs) were selected on the basis of their reported specificity for melanoma-associated antigens and activity in formalin-fixed, paraffin-embedded human tissue. An exception was Moab 225.288, which has not been reported to stain other than frozen sectioned tissue but is reported to cross-react with guinea pig melanoma cells. 16 Antibodies tested were HMB-45 (Enzo Biochem, New York, NY);IO HMB-50 (A. Gown, University of Washington, Seattle, WA);Z5 human melanosome-specific antigen (HMSA)-1 , I HMSA-5,I4 NKI/C3, and NKI/beteb (Dimension Laboratories, Mississauga, ON);z3.24 and 225.28s (Sorin Biomedica, Saluggia, Italy)." All seven antibodies are murine IgG Moabs raised against either human melanoma metastases (HMB- The immunohistochemical staining activity of the Moabs was tested initially on 13 well-differentiated, formalin-fixed, paraffin-embedded canine melanocytic tumors chosen from the archives of the Pathology Department, Western College of Veterinary Medicine, Saskatoon, Saskatchewan, and one or both of two human melanomas obtained from the Royal University Hospital, Saskatoon, Saskatchewan. The canine tumors included seven oral, three cutaneous, and two intraocular tumors and one pulmonary metastasis from an oral tumor. The amount of melanin varied among tumors and within tumors from slight to abundant. Tumors containing a majority of heavily pigmented cells were excluded because chromogen development was difficult to discern in these cells. Cell morphology varied among the canine tumors and included fusiform, dendritic, and epithelioid cells. Histopathologic criteria of malignancy were not considered in selecting canine melanocytic tumors. One human tumor consisted of predominantly spindle and stellate cells, and the other tumor was mostly large epithelioid cells.
Monoclonal antibodies HMSA-1 and HMSA-5, which stained a proportion of the canine tumors in the initial panel, were subsequently tested on tissue sections from an additional 22 canine melanomas, 35 nonmelanocytic canine tumors, and normal canine tissues ( Table 1 ). The 22 melanomas consisted of 14 cutaneous and seven oral tumors and one lymph node metastasis from an oral tumor. Nonmelanocytic tumors were chosen as representative of the major differential diagnoses at the sites where melanomas typically occur: the oral cavity and skin. Basal cell tumors were included because these tumors may contain many normal melanocytes as well as neoplastic epithelial cells that contain melanosomes.
Five-micrometer paraffin-embedded sections of canine and human tumors were applied to glass slides coated with 0.1% poly-D-lysine (MW 157,400, Sigma Chemical Co., St. Louis, MO). Sections were deparaffinized and rehydrated by sequential immersion in xylene, graded concentrations of ethanol, and tap water.
The tissue sections were immunohistochemically stained using a modification" of the avidin biotin peroxidase complex (ABC) method." Sections were incubated for 30 minutes at room temperature in a solution of 0.5% hydrogen peroxide in methanol to quench endogenous peroxidase activity, followed by washing three times in phosphate-buffered saline (PBS) (0.1 M, pH 7.4). The sections were subsequently treated with proteolytic enzymes or left untreated. Enzyme digestion involved incubating sections for 15 to 20 minutes at 37 C in protease (Type XIV, Sigma Chemical Co., St. Louis, MO) 0.05% in PBS (for Moabs HMB-50, NKI/C3, NKI/ beteb, HMSA-1, HMSA-5, and 225.288) or in trypsin (GIB-CO Laboratories, Paisley, Scotland) 0.1% in distilled water supplemented with CaClz 0.1%, pH 7.8, for 20 minutes (for Moabs HMB-45, HMB-50, HMSA-1, and HMSA-5) or 120 minutes (for Moabs HMB-45, HMB-50, HMSA-1, HMSA-5 , and 225.28s). The treatments tested were those previously reported for the various antibodies and those procedures that have provided optimum staining for other antigens in our (HMSA-5).
laboratory." All Moabs were tested on untreated tissue sections.
Slides were washed three times in PBS, and the sections were flooded with 4% normal horse serum (NHS) (GIBCO BRL Canada, Ltd., Burlington, ON) in PBS for 30 minutes at room temperature to saturate nonspecific protein-binding sites. Excess serum was drained, and the sections were flooded with anti-melanoma antibody diluted in PBS containing 4% NHS. Published dilutions were tested and then adjusted to provide optimum staining. Final antibody dilutions were 1:lOO for Moab HMB-45, 1:500 for Moab HMB-50, 1:lO for Moabs NKI/C3 and NKI/beteb, 1:20 for Moab 225.288, and 1:250 and 1:500 for Moab HMSA-1; Moab HMSA-5 was tested undiluted. The slides were incubated overnight at room temperature in a humid chamber.
Following three washes in PBS, sections were incubated for 30 minutes at room temperature flooded with biotinylated horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) diluted 1:400 in PBS containing 4% NHS. The slides were washed in PBS, followed by incubation in ABC solution prepared according to the manufacturer's instructions (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, CA) for 30 minutes. After washes in PBS, sections were incubated in 3-amino-9-ethylcarbazole (Zymed Laboratories, San Francisco, CA) for 12 minutes. The sections were counterstained with Mayer's hematoxylin and mounted in aqueous mounting medium (Crystal Mount, Biomeda, Foster City, CA).
Controls included serial sections of each tumor in which an isotype-matched irrelevant antibody was substituted for the anti-melanoma Moab. The human tumors were positive controls, and one or both were tested in conjunction with canine tissues.
Immunohistochemical staining was graded by estimating percentage of stained neoplastic cells as O%, less than 25%, 25-75%, and greater than 75% and by evaluating staining intensity as faint, moderate, or intense. Cells were considered positively stained with an anti-melanoma antibody, regardless of intensity, if comparable staining deposits were not seen in cells stained with the irrelevant antibody.
Additional sections of nonmelanocytic tumors and two canine melanomas, which had stained with Moab HMSA-1, were stained with periodic acid-Schiff, Chadwin's phosphotungstic acid hematoxylin, and Masson Fontana silver stain.
Results
Monoclonal antibodies (Moabs) HMSA-1 and HMSA-5 were the only antibodies that stained tumor cells in the initial 13 canine melanomas. In total, HMSA-5 and HMSA-1 stained 24/35 (69%) and 21/ 3 5 (60%) canine melanomas, respectively (Table 1) . Immunohistochemical staining of canine melanomas was not dependent on site of origin; primary skin, intraocular, and oral tumors and metastatic tumors were stained with one or both Moabs. Both Moabs stained a proportion of malignant and benign melanocytic tumors. Fifteen minutes of protease digestion of tissue sections gave optimum staining. t One lymph node metastasis and one pulmonary metastasis.
* All originating from the tongue.
Canine melanoma staining with HMSA-5 was heterogeneous and was generally more intense than with HMSA-1 ( Table 2) . HMSA-5 resulted in faint to intense granular to homogeneous cytoplasmic staining oftumor cells (Fig. 1) . In some tumors, HMSA-5 stained foci of pigmented cells; however, HMSA-5 usually showed little staining of heavily pigmented cells and most frequently stained cells within amelanotic areas of tumor sections. Nests of tumor cells within the overlying epidermis were also stained (Fig. 2) . HMSA-5 did not stain melanophages.
HMSA-1 staining of canine melanocytic tumors was also heterogeneous, with less than 25% of tumor cells stained in the majority of tumors (Table 2 ). Scattered cells showed faint to moderate, patchy to diffuse slightly granular cytoplasmic staining. In some tumor sections, small nests of cells stained (Fig. 3) . This antibody predominantly stained lightly pigmented and amelanotic tumor cells, similar to staining with HMSA-5. Occasionally, some melanophages were moderately In addition to melanomas, HMSA-5 stained melanocytes and some melanin-containing tumor cells in the one pigmented basal cell tumor examined. This antibody did not stain any other nonmelanocytic tumor (Table 1 ). In contrast, HMSA-1 stained 10/35 nonmelanomas ( Table 1) . In most cases, staining was of multiple, often fine cytoplasmic droplets of various sizes (Fig. 4) . Some of the cells in one granular cell tumor also had diffuse cytoplasmic staining. The material in all nonmelanocytic tumors was shown to be 
Discussion
This study has shown that two monoclonal antibodies (Moabs) to human melanoma-associated antigens may be used for immunohistochemical staining of formalin-fixed, paraffin-embedded canine melanomas. Monoclonal antibodies HMSA-1 and HMSA-5 bind epitopes on melanosomal glycoproteins in normal (HMSA-5) and neoplastic (HMSA-1 and HMSA-5) human melanocytes.lJ4 Consequently, these Moabs HMSA-1 stained 29% (1 0/35) of the nonmelanocytic tumors tested, thus specificity for melanoma discrimination is 71%. However, the staining in 9/10 nonmelanocytic tumors occurred as discrete cytoplasmic droplets and was readily distinguishable from the granular cytoplasmic staining seen in melanomas. Consequently, the specificity of this antibody for the detection of melanoma in practice may be comparable to that of HMSA-5. The one granular cell tumor, in which some cells had diffuse cytoplasmic HMSA-1 staining, was distinguishable from tumors of melanocytic lineage on the basis of its strong periodic acid-Schiff reaction.
HMSA-1 and HMSA-5 appear to bind to different antigens in canine tissues. These antibodies differ in staining patterns in melanomas, nonmelanocytic tumors, and normal canine tissues. In canine melanomas stained by both Moabs, rarely were the same cell populations stained. Recognition of different tumor-associated antigens by Moabs is beneficial because the Moabs will compliment one another in melanoma detection.
HMSA-5 staining in canine melanomas was of amelanotic or lightly pigmented cells as opposed to heavily pigmented cells. These findings are consistent with the known expression of HMSA-5 antigen in early melanosoma1 stages in human normal and neoplastic melanocytes.I4 Early stages of human melanosomes, usually containing little or no melanin, express the HMSA-5 epitope to a greater extent than do late melanosomal stages. Consequently, this antibody may prove to be especially useful in the identification of amelanotic melanomas.
The staining patterns of HMSA-5 and HMSA-1 of canine melanocytes are similar to their staining of human me1an0cytes.l.~~ However, in contrast to the present findings in canine tissues, HMSA-1 was not reported to stain normal human tissues. ' HMSA-1 staining of some normal canine tissues probably reflects species variation in epitope expression.
The other five Moabs tested failed to stain 13 different formalin-fixed, paraffin-embedded canine melanomas. Monoclonal antibodies HMB-45, HMB-50, NKI/C3, and NKI/beteb are capable of immunohistochemically staining routinely fixed human melanomas, although the staining activity of NKI/beteb is reduced in formalin-fixed tissues. 10.23- 25 These findings were confirmed in the present study. The absence of staining in canine melanomas suggests that either the antigens recognized by these antibodies are not expressed by neoplastic canine melanocytes at levels detectable by the methodology employed, or the antigens are destroyed by formalin-fixation. The Moab 225.28s recognizes an epitope on human high molecular weight melanoma-associated antigen. 27 This Moab has been shown to detect a corresponding antigenic determinant in cultured guinea pig melanoma cells and in basal cells of epidermis and hair follicles of normal guinea pig skin. 16 The inclusion of 225.283 in this study was based on this evidence of epitope conservancy among species. The absence of staining with 225.28s in the two human melanomas tested may be a reflection of the low number of tumors examined or may indicate that the antigenic determinant recognized by this Moab is destroyed by formalin fixation.
The immunohistochemical staining with HMSA-1 and HMSA-5 in canine tissues is similar to that of a recently described antibody, Moab IBF9, derived following mouse immunization with cultured canine melanoma cells. IBF9 immunohistochemically stained 24/38 (63%) formalin-fixed, paraffin-embedded canine melanomas, a proportion of tumors similar to that t monoclonal antibody HMSA-1. Melanin is brown. Avidin biotin preoxidase complex method with 3-amino-9-ethylcarbazole as chromogen. Mayer's hematoxylin counterstain. Bar = 50 pm.
Mucocutaneous plasmacytoma; dog. Monoclonal antibody HMSA-1 staining consists of discrete cytoplasmic droplets. Avidin biotin peroxidase complex method with 3-amino-9-ethylcarbazole as chromogen. Mayer's hematoxylin counterstain. Bar = 25 um. stained by HMSA-1 or HMSA-5. Perhaps the sensitivity for canine melanoma detection would be further enhanced if these three antibodies were combined.
Monoclonal antibodies HMSA-1 and HMSA-5, raised to epitopes on h u m a n melanoma-associated antigens, stained some melanoma cells in most formalinfixed, paraffin-embedded canine melanocytic tumors. These antibodies m a y provide a useful immunohistochemical stain for the improved diagnosis of canine melanoma.
